Company intelligence / Profile preview

MediSix Therapeutics

Ownership: Private
Employees: ~11
Development stage: Other

Overview

MediSix has developed proprietary technologies such as PEBL to address challenges in CAR-T cell therapy for T-cell malignancies. The company remains preclinical with a robust research pipeline but has not yet reported clinical trial results.

Therapeutic areas: ImmunologyOncology
Modalities: CAR-T cell therapyCell therapy
Industry: Biotech

Drug pipeline

5 assets

PCART3

Preclinical

4 more assets in the full pipeline.

Request access →

Partnerships

Not publicly disclosed as of June 2025.

Beyond the preview

Go deeper on MediSix Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MediSix Therapeutics.

Explore the full profile